{"id":"W3116484428","doi":"10.1177/1756287220980192","title":"Enfortumab Vedotin in urothelial cancer","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Oncology; Internal medicine; Clinical trial; Durvalumab; Cancer; Urothelial cancer; Rash; Population; Bladder cancer; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000356172,0.0004877988,0.0008287738,0.001505007,0.0001743447,0.0006328621,0.000501955,0.0006016762,0.004753205],"category_scores_gemma":[0.0004047489,0.0001733599,0.0006004823,0.001094961,0.0001723346,0.0006064412,0.0004503162,0.001002623,0.001490339],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000363121,"about_ca_system_score_gemma":0.0006944964,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008347653,"about_ca_topic_score_gemma":0.002228026,"domain_scores_codex":[0.9998804,0.00002292955,0.00001986622,0.0000201957,0.00004229824,0.00001417007],"domain_scores_gemma":[0.9998895,0.00005008363,0.00002241342,0.000002773172,0.00002548323,0.000009711859],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001069753,0.00006512322,0.0001239395,0.02534272,0.0001148935,0.0001421626,0.00004233537,0.0002875504,0.001822797,0.001536175,0.01597443,0.954441],"study_design_scores_gemma":[0.00006235341,0.000210789,0.001056829,0.007038854,0.0002854716,0.001397352,0.00004263617,0.000136177,0.0008891248,0.001014724,0.9878516,0.00001416314],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002857512,0.9982755,0.0000643032,0.0001592464,0.0001052235,0.000007236822,0.00002767635,0.000008131567,0.001066991],"genre_scores_gemma":[0.001609595,0.9972466,0.0001311221,0.0001994467,0.00005979192,0.00000938183,0.00005280011,0.000001568364,0.0006897313],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004753205,"threshold_uncertainty_score":0.01590103,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05086007436376948,"score_gpt":0.4063818328462285,"score_spread":0.355521758482459,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}